-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PEDELBUXg/OlQOQwG+d92qxvERLoCdZ0BRSTDmsCHepU2jqFqNWoJhEX+/ol8dTl fIOhNnCDzYnXv24tOhIdFg== 0000950129-03-003862.txt : 20030731 0000950129-03-003862.hdr.sgml : 20030731 20030731161553 ACCESSION NUMBER: 0000950129-03-003862 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20030731 ITEM INFORMATION: ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20030731 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LEXICON GENETICS INC/TX CENTRAL INDEX KEY: 0001062822 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 760474169 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-30111 FILM NUMBER: 03814799 BUSINESS ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 BUSINESS PHONE: 2818633000 MAIL ADDRESS: STREET 1: 8800 TECHNOLOGY FOREST PLACE CITY: THE WOODLANDS STATE: TX ZIP: 77381 8-K 1 h07836e8vk.txt LEXICON GENETICS INCORPORATED - JULY 31, 2003 - -------------------------------------------------------------------------------- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): JULY 31, 2003 LEXICON GENETICS INCORPORATED (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) DELAWARE 000-30111 76-0474169 (STATE OR OTHER JURISDICTION OF (COMMISSION FILE NUMBER) (I.R.S. EMPLOYER INCORPORATION OR ORGANIZATION) IDENTIFICATION NUMBER) 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS, TEXAS 77381 (ADDRESS OF PRINCIPAL EXECUTIVE OFFICES AND ZIP CODE) (281) 863-3000 (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE) - -------------------------------------------------------------------------------- ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS (c) Exhibits EXHIBIT NO. DESCRIPTION - ----------- ----------------------------------------------------- 99.1 -- Press Release of Lexicon Genetics Incorporated dated July 31, 2003 ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION On July 31, 2003, we issued a press release to report our financial results for the quarter ended June 30, 2003. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1. The information in this Form 8-K and the Exhibit attached to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. 2 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. LEXICON GENETICS INCORPORATED Date: July 31, 2003 By: /s/ JEFFREY L. WADE ------------------------------- Jeffrey L. Wade Executive Vice President and General Counsel 3 INDEX TO EXHIBITS
EXHIBIT NO. DESCRIPTION - ----------- ---------------------------------------------------- 99.1 -- Press Release of Lexicon Genetics Incorporated dated July 31, 2003
EX-99.1 3 h07836exv99w1.txt PRESS RELEASE DATED JULY 31, 2003 EXHIBIT 99.1 LEXICON GENETICS REPORTS SECOND QUARTER 2003 FINANCIAL RESULTS THE WOODLANDS, TEXAS, JULY 31, 2003 - Lexicon Genetics Incorporated (Nasdaq: LEXG), a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease, today reported financial results for the three and six months ended June 30, 2003. REVENUES: Lexicon's revenues for the three months ended June 30, 2003 were $8.9 million, a five percent decrease from $9.4 million for the corresponding period of 2002. The decrease of $0.5 million was primarily the result of higher revenues in the 2002 period from technology license agreements. For the six months ended June 30, 2003, total revenues were $17.0 million, effectively even with $17.1 million for the corresponding period of 2002. Revenues for the three months ended June 30, 2003 included: o subscription and license fees of $4.3 million, consisting primarily of access fees from the Company's LexVision(R) collaborations and technology license fees from sublicenses of the Company's gene targeting technology; and o collaborative research revenues of $4.6 million, consisting primarily of revenues from Lexicon's therapeutic protein collaborations and revenues from functional genomics collaborations with pharmaceutical and biotechnology companies. RESEARCH AND DEVELOPMENT EXPENSES: Research and development expenses for the three months ended June 30, 2003 increased nine percent to $20.8 million from $19.0 million for the corresponding period of 2002. The increase primarily reflects the expansion of the Company's drug discovery programs. For the six months ended June 30, 2003, research and development expenses increased 13 percent to $40.6 million from $35.9 million for the corresponding period of 2002. Research and development expenses included non-cash, stock-based compensation expense of $1.3 million and $2.6 million in the three and six months ended June 30, respectively, in both 2003 and 2002. GENERAL AND ADMINISTRATIVE EXPENSES: General and administrative expenses were $6.0 million for the three months ended June 30, 2003 even with the $6.0 million in the corresponding period of 2002. For the six months ended June 30, 2003, general and administrative expenses decreased two percent to $11.8 million from $12.0 million for the corresponding period of 2002. General and administrative expenses included non-cash, stock-based compensation expense of $1.3 million and $2.6 million in the three and six months ended June 30, respectively, in both 2003 and 2002. INTEREST AND OTHER INCOME, NET: Interest and other income, net decreased to $0.2 million in the three months ended June 30, 2003 from $0.7 million in the corresponding period of 2002 due to lower average cash and investment balances, lower average interest rates, and the accrual of interest expense under the December 2002 loan from Genentech, Inc. For the six months ended June 30, 2003, interest and other income, net decreased to $0.6 million from $1.8 million in the corresponding period of 2002. NET LOSS: Net loss was $17.6 million, or $0.34 per share, in the three months ended June 30, 2003, compared to a net loss of $14.9 million, or $0.29 per share, in the corresponding period of 2002. For the six months ended June 30, 2003, net loss was $34.8 million, or $0.66 per share, compared to a net loss of $29.0 million, or $0.56 per share, in the corresponding period of 2002. Excluding non-cash, stock-based compensation charges, net loss for the three months and six months ended June 30, 2003 was $15.1 million and $29.7 million, respectively, or $0.29 and $0.57 per share, compared to a net loss of $12.4 million and $23.9 million, or $0.24 and $0.46 per share, for the corresponding periods of 2002. As a complement to reporting net loss and net loss per common share in accordance with generally accepted accounting principles, or GAAP, Lexicon provides net loss and net loss per common share results excluding non-cash, stock-based compensation. Lexicon uses these measures in establishing budgets and believes they are useful in measuring the performance of the Company's business. A reconciliation of these results to GAAP is included in the selected financial data set forth below. CASH AND INVESTMENTS: As of June 30, 2003, Lexicon had approximately $95.6 million in cash and investments, including restricted cash and investments, compared to $107.6 million as of March 31, 2003 and $123.1 million as of December 31, 2002. Restricted cash and investments were $57.7 million on each of these dates. In July 2003, Lexicon completed a 10.0 million share common stock offering, raising a total of $49.0 million in net proceeds. "Fortified with additional capital, we look forward to continued successful implementation of our drug discovery business model in the second half of 2003," said Julia P. Gregory, executive vice president and chief financial officer of Lexicon. "We have a significant opportunity to commercialize our breakthrough discoveries and form major drug discovery alliances in selected therapeutic areas." SECOND QUARTER 2003 HIGHLIGHTS: "During the second quarter, we built significant momentum as we moved aggressively along the drug development pathway," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon. "We appointed two key additions to our clinical development team, Dr. Philip Brown as vice president of clinical development and Dr. William Heydorn as vice president of preclinical development. These individuals along with Dr. Alan Nies, chairman of Lexicon's medical advisory board and former head of clinical sciences at Merck, are in position to rapidly and efficiently advance our promising drug discovery programs." DISCOVERY OF A DRUG TARGET FOR LEARNING AND MEMORY: Lexicon announced the discovery of a new in vivo-validated drug target for learning and memory that could have applications in Alzheimer's and other cognitive disorders. Lexicon scientists discovered that inhibiting the LG617 protein in knockout mice resulted in a statistically significant increase in performance in a test of learning and memory, even as they age. Lexicon's LG617 gene encodes a membrane protein that is expressed only in the brain. Lexicon scientists are currently working to develop small molecule drugs against the human target that could have the potential to increase learning, attention and/or memory in patients with various disorders associated with cognitive impairment. APPOINTMENT OF VICE PRESIDENTS OF PRECLINICAL AND CLINICAL DEVELOPMENT: Lexicon appointed Philip M. Brown, M.D., J.D. as vice president of clinical development and William E. Heydorn, Ph.D. as vice president of preclinical development. Dr. Brown brings Lexicon more than a decade of experience in managing medical affairs, drug safety and clinical programs in the pharmaceutical industry, having advanced compounds from preclinical studies into clinical development and managed programs from IND through product commercialization. Dr. Heydorn brings Lexicon more than 15 years of experience in preclinical and clinical drug development, pharmaceutical operations, project management and regulatory affairs in the pharmaceutical industry, having been responsible for filing new drug applications (NDAs) for candidates in depression, anxiety, Alzheimer's disease, hypertension and acute pain. LICENSED GENE TARGETING TECHNOLOGY TO AVENTIS PHARMACEUTICALS INC.: Lexicon granted Aventis Pharmaceuticals Inc. a non-exclusive sublicense under patents covering the use of Lexicon's gene targeting technologies for use in Aventis' internal research. RECEIVED COMPUTERWORLD 21ST CENTURY ACHIEVEMENT AWARD FOR MEDICINE: Lexicon received Computerworld's 2003 21st Century Achievement Award for visionary use of information technology in medicine. Lexicon was chosen by a panel of distinguished judges from more than 400 nominations submitted this year. 5 LEXICON CONFERENCE CALL: Dr. Arthur T. Sands, president and chief executive officer, and Julia P. Gregory, executive vice president and chief financial officer, will review Lexicon's operating highlights and financial results for the six months ended June 30, 2003 and will discuss the company's expectations for the third quarter in a telephone conference call at 5:00 p.m. EDT today, July 31, 2003. The audio web cast can be heard by logging on to www.lexicon-genetics.com. It will be archived and available for review on line through August 7, 2003. Conference call participants may dial: 888/855-5428 (domestic USA), 719/457-2665 (international). A replay of the call will be available through August 7, 2003. Replay numbers: 888/203-1112 (domestic USA), 719/457-0820 (international). Pass code for all callers: 455458. ABOUT LEXICON GENETICS Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is using gene knockout technology to systematically discover in living mammals, or in vivo, the physiological functions and pharmaceutical utility of genes. The Company's gene function discoveries fuel therapeutic discovery programs in diabetes, obesity, cardiovascular disease, immune disorders, neurological disease and cancer. Lexicon has established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize its technology and turn its discoveries into drugs. Additional information about the Company is available through Lexicon's corporate website, www.lexicon-genetics.com. SAFE HARBOR STATEMENT This press release contains "forward-looking statements," including statements about Lexicon's growth and future operating results, discovery and development of products, strategic alliances, and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to develop drug candidates from its discoveries, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Business - Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2002, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. # # # CONTACT FOR LEXICON GENETICS: Chas Schultz, Director Investor Relations and Financial Analysis 281/863-3421 cschultz@lexgen.com LEXICON GENETICS INCORPORATED SELECTED FINANCIAL DATA
THREE MONTHS ENDED SIX MONTHS ENDED CONSOLIDATED STATEMENTS OF OPERATIONS DATA JUNE 30, JUNE 30, (In thousands, except per share data) 2003 2002 2003 2002 ---------- ---------- ---------- ---------- (UNAUDITED) (UNAUDITED) Revenues: Subscription and license fees ....................................... $ 4,310 $ 4,975 $ 7,412 $ 8,370 Collaborative research .............................................. 4,590 4,267 9,583 8,523 Compound libraries and other ........................................ 21 169 32 174 ---------- ---------- ---------- ---------- Total revenues .................................................... 8,921 9,411 17,027 17,067 Operating expenses: Research and development, including stock-based compensation of $1,285, $1,267, $2,555 and $2,574, respectively ................... 20,794 19,032 40,628 35,896 General and administrative, including stock-based compensation of $1,276, $1,276, $2,552 and $2,558, respectively ................... 5,979 6,019 11,783 11,988 ---------- ---------- ---------- ---------- Total operating expenses .......................................... 26,773 25,051 52,411 47,884 ---------- ---------- ---------- ---------- Loss from operations ................................................... (17,852) (15,640) (35,384) (30,817) Interest and other income .............................................. 316 702 784 1,822 Interest expense ....................................................... (83) (2) (164) (4) ---------- ---------- ---------- ---------- Net loss ............................................................... $ (17,619) $ (14,940) $ (34,764) $ (28,999) ========== ========== ========== ========== Adjustment for stock-based compensation (1) ............................ 2,561 2,543 5,107 5,132 ---------- ---------- ---------- ---------- Net loss, excluding stock-based compensation (1) ....................... $ (15,058) $ (12,397) $ (29,657) $ (23,867) ========== ========== ========== ========== Net loss per common share, basic and diluted ........................... $ (0.34) $ (0.29) $ (0.66) $ (0.56) ========== ========== ========== ========== Net loss per common share, excluding stock-based compensation (1) ...... $ (0.29) $ (0.24) $ (0.57) $ (0.46) ========== ========== ========== ========== Shares used in computing net loss per common share ..................... 52,496 52,250 52,434 52,188
CONSOLIDATED BALANCE SHEET DATA AS OF JUNE 30, AS OF DECEMBER 31, (In thousands) 2003 2002 ------------------ ------------------ (UNAUDITED) Cash and investments, including restricted cash and investments of $57,708 and $57,710, respectively ................................... $ 95,636 $ 123,096 Property and equipment, net ............................................ 34,401 37,362 Goodwill ............................................................... 25,798 25,798 Intangible assets other than goodwill, net ............................. 3,640 4,240 Total assets ........................................................... 173,394 201,772 Deferred revenue ....................................................... 17,038 18,647 Long-term debt ......................................................... 4,000 4,000 Deferred stock compensation ............................................ (5,988) (11,106) Accumulated deficit .................................................... (184,509) (149,745) Total stockholders' equity ............................................. 140,322 169,902
(1) In addition to reporting net loss and net loss per common share in accordance with generally accepted accounting principles, or GAAP, Lexicon provides net loss and net loss per common share excluding non-cash, stock-based compensation expense. -----END PRIVACY-ENHANCED MESSAGE-----